A recent report published by Infinium Global Research on paroxysmal nocturnal hemoglobinuria (PNH) treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional paroxysmal nocturnal hemoglobinuria treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional paroxysmal nocturnal hemoglobinuria treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global paroxysmal nocturnal hemoglobinuria treatment market. According to the report, the global paroxysmal nocturnal hemoglobinuria treatment market is projected to grow at a CAGR of 11.6% over the forecast period of 2019-2025.
Paroxysmal nocturnal hemoglobinuria is a rare acquired,
life-threatening disease of the blood. The disease is characterized by the
destruction of red blood cells (hemolytic anemia), blood clots (thrombosis),
and impaired bone marrow function (State where blood components do not form inadequate proportion). PNH affects 0.5-1.5 persons per million of the population
and is mainly a disease of younger adults. PNH occurs when mutations of a gene
called PIG-A occur in a bone marrow stem cell. The function of Stem cells
includes the production of mature blood elements like red blood cells, white
blood cells, and platelets. Thus the mutated stem cells pass the PIG-A mutation
to all cells derived from an abnormal stem cell. Cells carrying PIG-A mutations
are deficient with GPI-anchored proteins, which play an important role in the
protection of RBCs from destruction, blood clotting and involved in fighting
against infection. The survival rate in younger adults after diagnosis is 10
years, however, some patients can survive for decades with only minor symptoms.
The high growth of the paroxysmal nocturnal hemoglobinuria treatment
market will attribute by factors such as the rising number of blood and bone
marrow related disorders. National Organization for Rare Diseases (NORD) report
states around 0.5-1.5 per million general population suffer from PNH. Other
factors will contribute to the market growth is development in stem cell
research, advancement in stem cell transplantation therapies and heavy
investments for novel drug discovery (NDD). APL-2, a Complement C3 Inhibitor by
Apellis pharmaceuticals is under clinical trial phase 3 for the potential
treatment of paroxysmal nocturnal hemoglobinuria. However high costs
associated with medical treatment and adverse side effects with existing
treatments can hamper the growth of the market. On the other hand, unmet demand
for drugs in developing countries can provide better growth opportunities to the paroxysmal
nocturnal hemoglobinuria treatment market.
Based on geography North America, specifically, the US will
hold the highest share of the market in the near future, factors such as approval
for novel drugs in the pipeline, adoption of novel therapeutics will support
the growth of the region in the forecast period. The market in Europe is
anticipated to grow with a healthy rate in the near future, pharma major
collaboration with research institutes for new drug development and high
expenditure on the healthcare sector will contribute to the growth of the
market. The Asia-Pacific region is expected to be on the second spot in the paroxysmal nocturnal hemoglobinuria treatment market in the forecast period. An
increase in healthcare expenditure, the presence of key pharma players, and
rising healthcare awareness is contributing to the growth of this region.
The report on the global paroxysmal nocturnal hemoglobinuria
treatment market covers segments such as diagnostic test and treatment. On the
basis of diagnostic test, the sub-markets include complete blood count test
(CBC), lactate dehydrogenase test (LDH), bone marrow examination, urine test
for hemosiderin, flow cytometry, and other tests. On the basis of treatment,
the sub-markets include medication, stem cell transplant, and blood
transfusion.
The report provides profiles of the companies in the market
such as F. Hoffmann-La Roche AG, Akari Therapeutics, Alexion Pharmaceuticals,
lnc., Ra Pharmaceuticals, Novartis AG, Alnylam Pharmaceuticals, Inc., Apellis
Pharmaceuticals, Achillion Pharmaceuticals, Regeneron Pharmaceuticals, Inc.,
and Other Companies.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of paroxysmal
nocturnal hemoglobinuria treatment market. Moreover, the study highlights
current market trends and provides forecast from 2019-2025. We also have
highlighted future trends in the market that will affect the demand during the
forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.
Please Choose One of them.